This Trial is Conducted in Asia. The Aim of This Trial is to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs.
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2017
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL™ II Japan
- Sponsors Novo Nordisk
- 22 Nov 2017 Status changed from active, no longer recruiting to completed.
- 01 Nov 2017 Planned primary completion date changed from 3 Oct 2017 to 15 Nov 2017.
- 10 Jun 2017 Biomarkers information updated